Owner Scorecard


← All companies ← ICLR Manual IFS → ← IDYA Pharmaceuticals IMMP →

IFRX, InflaRx N.V.

Pharmaceuticals consumer brand Unprofitable

We are a biopharmaceutical company applying our proprietary technologies to discover, develop and commercialize first-in-class, highly potent and specific inhibitors of the complement activation factor known as C5a and its receptor C5aR.

Activation of the complement system ultimately results in the generation of C5a and C5b by cleavage from complement factor C5.

The C5a/C5aR1 signaling axis is central to this and therefore a critical component of the innate immune system.

Latest annual: FY2025 20-F · figures as filed, in EUR
IFRX · InflaRx N.V.
I

The business

What it sells, where the money comes from, the kind of company it is.

Revenue · FY2025
€29K
−82.3% YoY
Vital signs · TTM
Cash & investments €55M
Cash burn · annual €35M
Runway 1.6 yrs

The business in brief

read the 10-K →

What this business is and what moves its needle, from its own SEC filings.

Situation
Unprofitable. No meaningful revenue yet; the record is the cash on hand against the burn.
What moves the needle
Operating margin has run around −71182% through the cycle, the operating line deeply negative — so the lever is the path to a margin at all: revenue growth against the cost curve and the cash runway, not the level of a margin that isn't there yet. Inventory runs near 17178% of sales, so how fast it turns back into cash — and the risk of writing it down when demand softens — sits alongside the margin. Read this kind of business on the pipeline against the patent cliff, and pricing. On its own account, the filing leans hardest on pricing power & competition, set against the numbers in what the filing emphasizes, below.

Every line is arithmetic on the company's filings, shown in full in the sections below.

II

The record

Ten years of arithmetic, read across the cycle.

The record, 2023–2025

realized figures from each filing · older years to the left
2023’232024’242025’25TTMTTMDec 2025
Income statement
€63K€166K€29K€29KRevenueRevenue
(€45M)(€46M)(€46M)(€45M)Operating incomeOp. inc.
n/mn/mn/mn/mOperating marginOp. mgn
(€43M)(€46M)(€46M)(€46M)Net incomeNet inc.
Cash flow & returns
(€38M)(€49M)(€35M)(€35M)Operating cash flowOp. cash
€378K€387K€342K€342KDepreciationDeprec.
€4M(€3M)€10M€10MWorking capital & otherWC & other
€81K€47K€116KCapexCapex
128.5%28.3%394.4%Capex / revenueCapex/rev
(€38M)(€49M)(€35M)Owner earningsOwner earn.
n/mn/mn/mOwner earnings marginOE mgn
(€38M)(€49M)(€35M)Free cash flowFCF
n/mn/mn/mFree cash flow marginFCF mgn
€2M€2MDividends paidDiv. paid
-578%-619%-636%-636%Return on equityROE
−609%−668%Retained to equityRetained/eq
Balance sheet
€52M€18M€16M€55MCash & investmentsCash+inv
€24K€24KReceivablesReceiv.
€11M€7M€5M€5MInventoryInvent.
€12M€11M€5M€5MAccounts payablePayables
(€607K)(€4M)(€361K)(€337K)Operating working capitalOper. WC
€109M€72M€54M€54MCurrent assetsCur. assets
€17M€14M€13M€13MCurrent liabilitiesCur. liab.
6.5×5.1×4.1×4.1×Current ratioCurr. ratio
€120M€76M€55M€55MTotal assetsAssets
-1260.5×-2228.9×-1161.7×-1144.5×Interest coverageInt. cov.
€7M€7M€7M€7MShareholders’ equityEquity
Per share
54.9M58.9M67.3M67.3MShares out (diluted)Shares
€0.00€0.00€0.00€0.00Revenue / shareRev/sh
€-0.78€-0.78€-0.68€-0.68EPS (diluted)EPS
€-0.69€-0.82€-0.53Owner earnings / shareOE/sh
€-0.69€-0.82€-0.53Free cash flow / shareFCF/sh
€0.04€0.03Dividends / shareDiv/sh
€0.00€0.00€0.00Cap. spending / shareCapex/sh
€0.13€0.13€0.11€0.11Book value / shareBVPS

The record, charted

FY2016–2025

Each measure over its full record; the current point and the worst year marked.

Share count
67Mpeak FY2025
ROIC
−52%low FY2019

Owner earnings vs. net income

Owner earningsNet income

The accountant's number, and the cash an owner can take; the gap is the tell.

(€35M)owner earningsvs.(€46M)net incomelow FY2024

Net income is the accountant's number; owner earnings is the cash an owner could take out. The walk between them, off the cash-flow statement, and whether the gap is widening or holding.

In fiscal 2025 the business turned a €46M loss into (€35M) of owner earnings: more cash than the profit line showed, after the non-cash charges and the capital it put back in.

FY2025FY2024FY2023FY2022FY2021
Reported net income(€46M)(€46M)(€43M)(€29M)(€46M)
Depreciation & amortizationnon-cash charge added back+€342K+€387K+€378K+€384K+€372K
Working capital & othertiming of cash in and out, other non-cash items+€10M−€3M+€4M−€5M+€5M
Cash from operations(€35M)(€49M)(€38M)(€34M)(€40M)
Capital expenditurecash put back in to keep running and to grow−€116K−€47K−€81K−€162K−€38K
Owner earnings(€35M)(€49M)(€38M)(€34M)(€40M)
Owner-earnings marginowner earnings ÷ revenue-120794%-29317%-60064%

Owner earnings is the cash an owner could pull out without starving the business: operating cash less the capital it must spend to hold its position .

Maintenance capex is estimated as depreciation where a growing business invests above it; free cash flow is the figure the scorecard's free-cash margin reads.

III

Quality & stewardship

Returns, the balance sheet, capital allocation, and pay.

Owner’s Scorecard

FY2025 20-F · source on SEC EDGAR →

Will it survive?

  • Does not cover its interest
    Operating income (€45M) ÷ interest expense €39K
    What this means

    A full year of operating profit didn't cover the interest bill. This is the zombie zone: the business depends on refinancing, asset sales, or forbearance to service its debt.

  • Net cash
    Cash €16M + ST investments €39M − debt €2M
    What this means

    Cash and short-term investments exceed every dollar of debt by €53M, on net the company owes nothing, and can act from strength when others can't. Net debt is the leverage figure that matters: the cash is already set against the debt. Strategic or illiquid investments aren't counted here.

  • Long (60+ days)
    DSO 295 + DIO 253 − DPO 271 days
    What this means

    Days cash is tied up between paying suppliers and collecting from customers. Lower is better; a long cycle means growth itself eats cash.

Is it a good business?

  • Not meaningful here
    Invested capital (€7M) = debt €2M + equity €7M − cash
    Industry peers: median -101%
    What this means

    Invested capital is near zero or negative, usually years of buybacks pulling equity down. ROIC explodes or flips sign and stops meaning anything. Judge this one on Owner Earnings instead.

  • Consumes cash through the cycle
    3-yr median margin, range -120794%–-29317%; latest (€35M) = operating cash (€35M) − maintenance capex €116K
    Industry peers: median -12417%
    What this means

    What an owner could take out without starving the business: operating cash less the maintenance capital it must spend to hold its position — Buffett's owner earnings. That's -120794% of revenue this year, a -60064% median across 3 years.

  • Loss, and burning cash
    Net income (€46M) · cash from operations (€35M)
    What this means

    The company reported a net loss, so a conversion ratio isn't meaningful. What matters then is whether operations still threw off cash, here, they did not.

How is the cash used?

  • No surplus to allocate
    What this means

    The business didn't generate positive Owner Earnings this year, so any distributions came from the balance sheet or borrowing, not from operations.

  • Investing or harvesting? 0.34×
    Harvesting
    Capex €116K ÷ depreciation €342K
    What this means

    Descriptive, not a grade. Above ~1× means investing faster than assets wear out (growth, or, sustained for years, today's earnings carrying less depreciation than tomorrow's will). Below means spending less than it's wearing out (efficiency, or a melting asset base). The ratio won't tell you which; the filings will.

Graham’s defensive tests · 2 of 4 met

Graham’s numerical criteria for the defensive investor (The Intelligent Investor, ch. 14), run on the filings. A floor of safety, not a buy signal; many fine modern businesses fail his strictest liquidity rules by design.

  • Adequate size
    Revenue ≥ $2B (a dollar floor) · €29K
    What this means

    Big enough to weather a storm. Graham's floor is a dollar figure — about $2B of revenue as a conservative modern stand-in. This company reports in its home currency and we carry no exchange rate, so we show the figure and leave the size bar for you to apply rather than convert it with a number we don't have.

  • Strong liquidity Pass
    Current ratio ≥ 2× · 4.13×
    What this means

    Current assets at least twice current liabilities, near-term bills covered without touching the business. Strict by design: many cash-rich modern firms run leaner and miss it, holding their cushion in longer-dated securities.

  • Conservative debt Pass
    Debt ≤ working capital · €2M vs €41M WC
    What this means

    Graham's rule that borrowings not exceed net current assets. Capital-heavy and buyback-heavy firms routinely fail it, read it next to interest coverage, not alone.

  • Earnings stability Miss
    A profit every year (10-yr record) · 10 loss years
    What this means

    Graham wanted earnings in each of the past ten years, the stability a defensive owner leans on.

  • Dividend record Miss
    Uninterrupted dividends · 2 of 10 yrs
    What this means

    An unbroken dividend was Graham's mark of durability. He wanted twenty years; the filings show about ten, and a single suspension breaks the streak. Non-payers, many fine modern compounders, fall outside his defensive net by design.

  • Earnings growth
    Earnings +33% over the record ·
    What this means

    Earnings were negative early in the record, a growth rate isn't meaningful.

  • Moderate price
    P/E ≤ 15 and P/E × P/B ≤ 22.5 · decided by the price
    What this means

    Graham's valuation gate, the wall he kept between a sound business and a sound investment. Three-year average earnings are €-0.62/share (latest year €-0.63), the averaged base the calculator's gate runs on, and book value is €0.10/share. Enter a price in “What the price implies” just below for the P/E, P/B, and whether it clears. But this is the rule Buffett outgrew: there's no hard P/E law, and a wonderful business can deserve a far richer multiple if the thesis holds, treat it as the bargain-hunter's floor, not a verdict on the price.

Does AI threaten the moat?

Low contestability

The moat is physical, regulated or balance-sheet-funded, the kind AI cuts costs within but does not contest.

In its own filing Raised, but not as a competitor

The filing raises AI among its risks, but in other terms (security, regulation, energy or the like), not as a competitor to its product.

AI is unlikely to contest a moat that is physical, regulated or balance-sheet-funded; here it reads more as a cost tool than a threat.

Read from the filing's own risk factors, paired with the industry's structure under its SIC code; the durability is read above, the price below.

All figures as filed; the source filing is linked above.

Current Position

as of fiscal year-end, Dec 31, 2025

Can the business pay what it owes this year, off the freshest balance sheet: the quality of the assets, the debt actually coming due, and what a low ratio means here.

Current assets€54M
  • Cash & short-term investments€55M
  • Receivables€24K
  • Inventory€5M
Current liabilities€13M
  • Accounts payable€5M
  • Other current liabilities€8M
Current ratio4.13×all current assets ÷ what's due · Graham looked for 2×
Quick ratio3.74×stricter: inventory excluded
Cash ratio4.25×strictest: cash alone against what's due
Working capital€41Mthe cushion left after near-term bills
Cash runway1.6 yrsthe business is consuming cash; this is how long the cash on hand lasts at that rate
Deeper floors
Tangible book value€7Mequity stripped of goodwill & intangibles
Net current asset value€40MGraham's net-net: current assets less all liabilities
Debt incl. operating leases€3M€898K of it operating leases

From the company's latest filing.

Peers, Pharmaceuticals

The same industry, side by side on owner economics. Each figure is a through-cycle median, so a peak or trough year can’t distort it; the group median at the foot is the line to read each against.

CompanyRevenueGross marginOp. marginROICOwner earn. margin
SGMTSagimet Biosciences Inc. Series A$2M-2844.5%-59%
GERNGeron Corporation$237K-5666.5%-30%-6875%
CADLCandel Therapeutics Inc.$125K-20580.8%-17960%
CNTBConnect Biopharma Holdings Limited$64K-90740.6%-1262%-80688%
AVTXAvalo Therapeutics Inc.$59K63%-1241.0%-97%-606%
ALTAltimmune Inc.$41K-577.1%-105%-189%
FBRXForte Biosciences Inc.$36K-37981.2%-545%-34751%
IFRXInflaRx N.V.€29K-71182.1%-52%-60064%
Group median-13123.7%-97%-17960%
IV

The price

What a price has to assume.

What the price implies

reverse-DCF

Enter the home-market price, not the US ADR quote. InflaRx N.V. reports in EUR, and every figure here (owner earnings, book value, the share count) is on that EUR, ordinary-share basis. Enter the price on the same basis: the local-exchange quote per ordinary share in EUR. A US ADR price in dollars bundles the ADR-to-ordinary ratio and the exchange rate, so it will not reconcile with these figures and would throw the multiple off.

The owner-earnings base could not be formed from this filing’s tagged data (operating cash flow or capital spending is missing), so the owner-earnings reverse-DCF has no base to grow. We read the price from both ends instead: type a price to see the profitability it demands, then set the mature margin you would believe and weigh the two against each other. Nothing leaves your browser unless you enter it in your notebook.

The assumptions

Enter a price to run it.

Owner earnings it must reach
Margin the price demands
Owner-earnings margin today

Two reads of one future. From your price: the owner earnings the company must reach, valued at a mature multiple and discounted back at your rate, expressed as the margin it implies on revenue grown at your rate. From your belief: the mature margin you would credit, set on the dial above. When the margin the price demands runs above the one you would believe, you are paying for a future taken on faith. For a deep cyclical at a trough, normalized through-cycle earnings are the better lens; this mode is for the genuinely unprofitable, and for the profitable business whose capital spending currently outruns its cash.

Cite: Owner Scorecard, "InflaRx N.V. (IFRX), the owner's record," https://ownerscorecard.com/c/IFRX, data as of 2026-07-09.

Manual order: ← ICLR its page in the Manual IFS →

Industry order: ← IDYA the Pharmaceuticals chapter IMMP →